Improving statistical power in severe malaria genetic association studies by augmenting phenotypic precision.


Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
06 07 2021
Historique:
received: 22 04 2021
accepted: 22 06 2021
pubmed: 7 7 2021
medline: 29 10 2021
entrez: 6 7 2021
Statut: epublish

Résumé

Severe falciparum malaria has substantially affected human evolution. Genetic association studies of patients with clinically defined severe malaria and matched population controls have helped characterise human genetic susceptibility to severe malaria, but phenotypic imprecision compromises discovered associations. In areas of high malaria transmission, the diagnosis of severe malaria in young children and, in particular, the distinction from bacterial sepsis are imprecise. We developed a probabilistic diagnostic model of severe malaria using platelet and white count data. Under this model, we re-analysed clinical and genetic data from 2220 Kenyan children with clinically defined severe malaria and 3940 population controls, adjusting for phenotype mis-labelling. Our model, validated by the distribution of sickle trait, estimated that approximately one-third of cases did not have severe malaria. We propose a data-tilting approach for case-control studies with phenotype mis-labelling and show that this reduces false discovery rates and improves statistical power in genome-wide association studies. In areas of sub-Saharan Africa where malaria is common, most people are frequently exposed to the bites of mosquitoes carrying malaria parasites, so they often have malaria parasites in their blood. Young children, who have not yet built up strong immunity against malaria, often fall ill with severe malaria, a life-threatening disease. It is unclear why some children develop severe malaria and die, while other children with high numbers of parasites in their blood do not develop any apparent symptoms. Genetic susceptibility studies are designed to uncover why such differences exist by comparing individuals with severe malaria (referred to as ‘cases’) with individuals drawn from the general population (known as ‘controls’). But severe malaria can be a challenge to diagnose. Since high numbers of malaria parasites can be found in healthy children, it is sometimes difficult to determine whether the parasites are making a child ill, or whether they are a coincidental finding. Consequently, some of the ‘cases’ recruited into these studies may actually have a different disease, such as bacterial sepsis. This ultimately affects how the studies are interpreted, and introduces error and inaccuracy into the data. Watson, Ndila et al. investigated whether measuring blood biomarkers in patients (derived from the complete blood count, including platelet counts and white blood cell counts) could improve the accuracy with which malaria is diagnosed. They developed a new mathematical model that incorporates platelet and white blood cell counts. This model estimates that in a large cohort of 2,220 Kenyan children diagnosed with severe malaria, around one third of enrolled children did not actually have this disease. Further analysis suggests that patients with severe malaria are highly unlikely to have platelet counts higher than 200,000 per microlitre. This defines a cut-off that researchers can use to avoid recruiting patients who do not have severe malaria in future studies. Additionally, the ability to diagnose severe malaria more accurately can make it easier to detect and treat other diseases with similar symptoms in children with high numbers of malaria parasites in their blood. Watson, Ndila et al.’s findings support the recommendation that all children with suspected malaria be given broad spectrum antibiotics, as many misdiagnosed children will likely have bacterial sepsis. It also suggests that using complete blood counts, which are cheap to obtain and increasingly available in low-resource settings, could improve diagnostic accuracy in future clinical studies of severe malaria. This could ultimately improve the ability of these studies to find new treatments for this life-threatening disease.

Autres résumés

Type: plain-language-summary (eng)
In areas of sub-Saharan Africa where malaria is common, most people are frequently exposed to the bites of mosquitoes carrying malaria parasites, so they often have malaria parasites in their blood. Young children, who have not yet built up strong immunity against malaria, often fall ill with severe malaria, a life-threatening disease. It is unclear why some children develop severe malaria and die, while other children with high numbers of parasites in their blood do not develop any apparent symptoms. Genetic susceptibility studies are designed to uncover why such differences exist by comparing individuals with severe malaria (referred to as ‘cases’) with individuals drawn from the general population (known as ‘controls’). But severe malaria can be a challenge to diagnose. Since high numbers of malaria parasites can be found in healthy children, it is sometimes difficult to determine whether the parasites are making a child ill, or whether they are a coincidental finding. Consequently, some of the ‘cases’ recruited into these studies may actually have a different disease, such as bacterial sepsis. This ultimately affects how the studies are interpreted, and introduces error and inaccuracy into the data. Watson, Ndila et al. investigated whether measuring blood biomarkers in patients (derived from the complete blood count, including platelet counts and white blood cell counts) could improve the accuracy with which malaria is diagnosed. They developed a new mathematical model that incorporates platelet and white blood cell counts. This model estimates that in a large cohort of 2,220 Kenyan children diagnosed with severe malaria, around one third of enrolled children did not actually have this disease. Further analysis suggests that patients with severe malaria are highly unlikely to have platelet counts higher than 200,000 per microlitre. This defines a cut-off that researchers can use to avoid recruiting patients who do not have severe malaria in future studies. Additionally, the ability to diagnose severe malaria more accurately can make it easier to detect and treat other diseases with similar symptoms in children with high numbers of malaria parasites in their blood. Watson, Ndila et al.’s findings support the recommendation that all children with suspected malaria be given broad spectrum antibiotics, as many misdiagnosed children will likely have bacterial sepsis. It also suggests that using complete blood counts, which are cheap to obtain and increasingly available in low-resource settings, could improve diagnostic accuracy in future clinical studies of severe malaria. This could ultimately improve the ability of these studies to find new treatments for this life-threatening disease.

Identifiants

pubmed: 34225842
doi: 10.7554/eLife.69698
pii: 69698
pmc: PMC8315799
doi:
pii:

Substances chimiques

Extracellular Matrix Proteins 0
FREM3 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Medical Research Council
ID : G0600230
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206194
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0601027
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UP_A390_1107
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT077383/Z/05/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 202800/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0600718
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12023/26
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 093956/Z/10/C
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 090770/Z/09/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M006212/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 204911/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0801439
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 209265/Z/17/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 203141/Z/16/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00004/05
Pays : United Kingdom

Informations de copyright

© 2021, Watson et al.

Déclaration de conflit d'intérêts

JW, CN, SU, AM, GN, SM, CN, NM, NP, BT, KR, SL, HK, EG, KM, ND, AD, PB, TW, CH, NW No competing interests declared

Références

PLoS Genet. 2013 May;9(5):e1003509
pubmed: 23717212
PLoS Med. 2012;9(8):e1001297
pubmed: 22927801
Elife. 2019 Jan 28;8:
pubmed: 30688212
Nat Protoc. 2007;2(10):2492-501
pubmed: 17947991
Arch Dis Child. 2016 Nov;101(11):1004-1009
pubmed: 27281455
Clin Infect Dis. 2020 Dec 3;71(9):e465-e470
pubmed: 32107527
Lancet. 2010 Nov 13;376(9753):1647-57
pubmed: 21062666
PLoS Med. 2006 May;3(5):e158
pubmed: 16605300
PLoS Genet. 2009 Jan;5(1):e1000360
pubmed: 19180233
Adv Data Anal Classif. 2019;13(1):33-64
pubmed: 31007770
Lancet Haematol. 2018 Aug;5(8):e333-e345
pubmed: 30033078
Am J Trop Med Hyg. 2002 Jun;66(6):686-91
pubmed: 12224575
Science. 2017 Jun 16;356(6343):
pubmed: 28522690
Lancet. 2011 Oct 8;378(9799):1316-23
pubmed: 21903251
PLoS Med. 2007 Aug;4(8):e251
pubmed: 17713980
Br J Haematol. 2009 Sep;146(6):675-82
pubmed: 19650883
Med Mal Infect. 2020 Mar;50(2):127-140
pubmed: 30885541
N Engl J Med. 1996 Jul 11;335(2):76-83
pubmed: 8649493
N Engl J Med. 2011 Jun 30;364(26):2483-95
pubmed: 21615299
Nat Med. 2004 Feb;10(2):143-5
pubmed: 14745442
Trends Parasitol. 2011 Jul;27(7):315-20
pubmed: 21429801
N Engl J Med. 1982 Feb 11;306(6):313-9
pubmed: 7033788
PLoS One. 2017 Jul 27;12(7):e0180758
pubmed: 28749962
Elife. 2018 Jul 25;7:
pubmed: 30044224
Nat Rev Genet. 2010 Feb;11(2):149-60
pubmed: 20084087
Elife. 2017 Jun 07;6:
pubmed: 28590246
Lancet Infect Dis. 2012 Jun;12(6):457-68
pubmed: 22445352
Stat Med. 1994 Nov 30;13(22):2345-58
pubmed: 7855468
Lancet. 2009 Feb 14;373(9663):557-66
pubmed: 19059639
Nat Genet. 2005 Nov;37(11):1253-7
pubmed: 16227994
PLoS Med. 2019 Aug 23;16(8):e1002858
pubmed: 31442221
Trop Med Int Health. 2014 Sep;19 Suppl 1:7-131
pubmed: 25214480
J Infect Dis. 2013 Jul 15;208(2):192-8
pubmed: 23585685
Malar J. 2010 Apr 15;9:97
pubmed: 20398339
Nat Genet. 2014 Nov;46(11):1197-204
pubmed: 25261933
BMC Med. 2015 Apr 24;13:97
pubmed: 25907925
Nat Commun. 2019 Feb 20;10(1):856
pubmed: 30787300
Nat Commun. 2019 Dec 16;10(1):5732
pubmed: 31844061
EBioMedicine. 2014 Nov 1;1(1):29-36
pubmed: 25893206
Elife. 2021 Jul 06;10:
pubmed: 34225842
Clin Microbiol Rev. 2002 Oct;15(4):564-94
pubmed: 12364370
Elife. 2017 Jan 09;6:
pubmed: 28067620
PLoS Med. 2007 Aug;4(8):e267
pubmed: 17713984
Malar J. 2007 Apr 30;6:51
pubmed: 17470294
Lancet Haematol. 2015 Oct;2(10):e437-44
pubmed: 26686045
Wellcome Open Res. 2020 Dec 9;5:287
pubmed: 34632085
Lancet. 2005 Aug 27-Sep 2;366(9487):717-25
pubmed: 16125588
Hum Genet. 2020 Jun;139(6-7):801-811
pubmed: 32130487

Auteurs

James A Watson (JA)

Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Carolyne M Ndila (CM)

Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Sophie Uyoga (S)

KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.

Alexander Macharia (A)

KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.

Gideon Nyutu (G)

KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.

Shebe Mohammed (S)

KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.

Caroline Ngetsa (C)

KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.

Neema Mturi (N)

KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.

Norbert Peshu (N)

KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.

Benjamin Tsofa (B)

KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.

Kirk Rockett (K)

The Wellcome Sanger Institute, Cambridge, United Kingdom.
Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.

Stije Leopold (S)

Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Hugh Kingston (H)

Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Elizabeth C George (EC)

Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom.

Kathryn Maitland (K)

KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.
Institute of Global Health Innovation, Imperial College, London, London, United Kingdom.

Nicholas Pj Day (NP)

Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Arjen M Dondorp (AM)

Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Philip Bejon (P)

Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.

Thomas N Williams (TN)

KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.
Institute of Global Health Innovation, Imperial College, London, London, United Kingdom.

Chris C Holmes (CC)

Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Department of Statistics, University of Oxford, Oxford, United Kingdom.

Nicholas J White (NJ)

Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH